Dextera Surgical — IPO Roadshow (April 2017)
27 slides from Dextera Surgical's IPO roadshow presentation, Apr 21, 2017
Slide 1: Dextera Surgical Investor Presentation April 2017
Dextera Surgical Investor Presentation April 2017 NASDAQ: DXTR
Slide 2: Forward Looking Statement
Forward Looking Statement 2 The following material contains forward - looking statements, including statements regarding Dextera Surgical’s future, business strategy, product development and plans and objectives of management for future operations. The words “may,” “continue,” “potential,” “estimate
Slide 3: Investment Overview
Investment Overview • Two proprietary medical technology platforms advancing minimally invasive surgery • MicroCutter – Smallest diameter articulating surgical stapler – $2 billion total WW surgical stapling market – 66 issued patents; CE Mark and 510(k) cleared – Intuitive Surgical license (paid $1
Slide 4: Growing Demand for Minimally Invasive Surgery
Growing Demand for Minimally Invasive Surgery Less pain, faster recovery & shorter hospital stays driving provider’s interest and patient demand for less invasive surgery Early diagnosis and detection leading patients and surgeons to look for less invasive approaches to treat smaller lesions Shift f
Slide 5: Minimally Invasive Surgery Technology Platforms
Minimally Invasive Surgery Technology Platforms Dextera developed and commercialized two technology platforms addressing the need for less invasive surgery Only FDA - cleared products for BOTH proximal & distal automated anastomoses of vessels in CABG procedures The first and only 5mm stapler with 8
Slide 6: Strategic Partners: Intuitive Surgical Co-development Agreement
Strategic Partners: Intuitive Surgical Co - development Agreement 6 NASDAQ:ISRG $27.4 billion market cap $2.7 billion in sales (FY’16) Intuitive Surgical (NASDAQ:ISRG) first licensed DXTR’s technology in August 2010 • Has received over $14MM from Intuitive Surgical for exclusive robotic application
Slide 7: Strategic Partners: B. Braun/Aesculap Strategic Partnership Agreement
Strategic Partners: B. Braun/Aesculap Strategic Partnership Agreement 7 Euro 6.4 Billion in sales (FY16) • Launched MicroCutter in Spain with B. Braun in Q1 CY17 • Preliminary discussions in progress for a strategic partnership, including: – Expansion of current distribution agreement for MicroCutte
Slide 8: Dextera has developed the world's smallest profile articulating surgical stapling device
… developed the world’s smallest profile articulating surgical stapling device to advance minimally invasive surgery so surgeons can improve patient outcomes. 8 Dextera has… 80º articulation • Up to 78% greater articulation • Increased angle of reach and unprecedented access to the surgical site 5mm
Slide 9: Size Matters for Minimally Invasive Surgery
Size Matters for Minimally Invasive Surgery 9 5mm 8mm 10 or 12mm 15mm Grasper Camera Clip Applier Sealing Device Current Staplers Current market Intuitive
Slide 10: Key Competitive Advantages
Smallest Surface Area Widest Articulation Broadest Reach Up to 51% smaller surface area At least 33% more reach Up to 78% greater articulation Key Competitive Advantages 10 Enabling MIS procedure approaches that are “not possible with either the JustRight stapler or conventional staplers” (Pediatric
Slide 11: Conventional Stapler Dimensions
Conventional Stapler Dimensions Driver Staple Tissue Gap Channel Anvil 11 Classic B - Staple Tine Length = Form Factor Current Endostaplers Green Anvil = 4mm Tissue Gap = 1.5mm Staple = 4.3mm Driver = 1.5mm Channel = 1.5mm 12.4mm
Slide 12: Unique Approach & Robust Intellectual Property
Unique Approach & Robust Intellectual Property Driverless deployment from staples - on - a - strip Staples shaped like a suture needle Staple deployed by wedge (no driver) making direct contact with staple Accurate motion frangibly separates staple from strip PATENTS U.S. 55 Issued 30 Pending Foreig
Slide 13: Market Opportunity
Market Opportunity 13 $2B global market for minimally invasive surgical stapling products growing at 8% CAGR through 2024 Source: IMS Data, Company Estimates & Grandview Research 2016
Slide 14: Large Addressable Market
Large Addressable Market 14 Total U.S. Surgeries Estimated 2,500,000 Procedures Annually Thoracic: 147k $1,500/procedure TAM: $220M Lobectomy/Segmentectomy: 95k Wedge Resection: 39k Esophagectomy: 7k Pediatric: 53k $1,400/procedure TAM: $74M Thoracic to Colorectal: 53k Parenchymal: 82k $1,050/proced
Slide 15: U.S. Endo Stapling Market
15 Source: IMS Data & Company Estimates U.S. Endo Stapling Market Staple Height U.S. ($MM) Mix Thin/Vascular $374 42% Medium $333 37% Thick $187 21% Total $894 100% White & blue sizes for cartridge reloads cover 79% of the US market 15
Slide 16: Commercialization Strategy
16 Thoracic KOLs in Leading Hospitals Drive Deeper Penetration in Existing Accounts Drive Growth in Target Geographies Innovators 150 cases/yr Early Adopters 100 cases/yr Fast Followers Laggards Commercialization Strategy 1 Focused approach for hospital entry 2 3 Expanding usage to Pediatric & Solid
Slide 17: MATCH Trial to Document Excellent Clinical Performance
MATCH Trial to Document Excellent Clinical Performance • Study evaluating hemostasis and procedure enabling aspects of MicroCutter 5/80 – Enrolled 43 of 60+ patients in world leading thoracic centers • Covers all procedure approaches to lobectomy – Robotic, uniportal, microlobectomy, anterior, poste
Slide 18: Dextera commercialized the only FDA cleared products for proximal & distal automated anastomoses
… commercialized the only FDA cleared products for BOTH proximal & distal automated anastomoses of vessels in CABG Procedures 18 Dextera has… C - Port xA ® Distal Anastomosis System • Enables automated, reliable, reproducible and compliant connections of blood vessels during CABG (coronary artery by
Slide 19: Strong Clinical Support for CABG Procedures
• Procedure stability driven by MIS technologies • Reduced incidence of post - op stroke • Reduce length - of - stay • Eliminate sternal access, wound infections • Maximize use of arterial grafts for improved patency rates Strong Clinical Support for CABG Procedures 19 700,000 Annual CABG Procedures
Slide 20: FY17 & FY18 Milestones
FY17 & FY18 Milestones 20 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 Execute strategic partnership with B. Braun Supply chain optimization & establish product capacity of 120 MCs/week Enrollment completed for MATCH Registry Expand MC indication to include liver in US Expand product pipeline Drive clinical adopti
Slide 21: Financial Highlights
$55k $282k $516k $700k - $800k Thousands 21 Financial Highlights FY16 Sales Cardiac products $2.2M MicroCutter products 0.4M License & royalty 1.5M Total Sales $4.1M MicroCutter FY17 Sales Forecast $1.5 - $1.6M
Slide 22: Balance Sheet & Cap Structure
Balance Sheet & Cap Structure Balance Sheet as of 12/31/16 Cash, Cash Equivalents & Investments $5.8M Total Assets $8.9M Current & Other Liabilities $4.5M LT Note Payable $4.0M Shareholders’ Equity $0.4M Shares Outstanding as of 12/31/16 Common Shares (Pre - offering) 8.9M Option & RSUs 1.6M Preferr
Slide 23: New Management Team: Proven Med-Tech Leaders
New Management Team: Proven Med - Tech Leaders Julian Nikolchev President, CEO & Director ( Oct. 2015 ) 23 • Founder, CEO & CTO of Pivot Medical, acquired by Stryker in 2014, now a leading product line for Stryker Sports Medicine Company • Served as a venture partner at Frazier Healthcare Ventures,
Slide 24: New Management Team: Proven Med-Tech Leaders
New Management Team: Proven Med - Tech Leaders Tom Palermo Chief Operating Officer ( Nov. 2015 ) • CEO, UlceRx Medical • President & CEO, ReVascular Therapeutics • VP, Operations & Engineering, Ensure Medical • New Hampshire College, BS Liam Burns VP, Sales & Marketing ( Jan. 2014 ) • VP Marketing,
Slide 25: Summary: Dextera At Inflection Point
Summary: Dextera At Inflection Point 25 • New management team with proven commercial track record • MicroCutter redesign completed, demonstrated improved performance and encouraging clinical feedback from target KOLs • Intuitive Surgical agreement validates and expands MicroCutter platform • Potenti
Slide 26: Breakthrough technologies to advance minimally invasive surgery
Breakthrough technologies to advance minimally invasive surgery
Slide 27: Board of Directors: Strong Team of Med-Tech Leaders
Board of Directors: Strong Team of Med - Tech Leaders Mike Bates Chairman • Moximed, consulting CFO, ‘08 - ’15 • St. Francis Medical, CFO, ‘05 - ’07 • Silicon Genetics, CFO, ‘00 - ’04 • Collagen Aesthetics, CFO, ‘99 - ’00 Greg Casciaro Director • Cardiac Dimensions, President & CEO, ‘15 - present •